Figure 3From: Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study Pain for treated and observed groups, and pain when treated group was subdivided based on pain of CBP decreasing (CBPd) or persisting (CBPp) after 2 weeks. A. Pain at baseline and after 2-weeks (visual analog score, VAS, 0-10 score) in CBP patients who received no interventions or treatment instructions, CBP observed (n = 15), in contrast to the patients who participated in the clinical trial for an ineffective treatment, CBP treatment (n = 30). The two groups started at a similar intensity of back pain but only the CBP treatment group showed decrease in back pain after two weeks. Error bars represent SEMs. * p ≪ 0.05. B. Back pain intensity, in CBPd and CBPp groups, as a function of treatment duration. A median split shows that on average the group that showed absolute pain change more than the median had significantly lower pain at the 2 week time point.Back to article page